Posts Tagged → Synthetic marijuana
With all the discord in Washington these days, it’s rare to see several US governmental organizations working together to address a significant public health problem.
This week, the US Drug Enforcement Agency (DEA) mobilized Operation Log Jam, an unusual and highly-coordinated action with six other federal agencies aimed to shut down the synthetic designer drug industry in 109 US cities. The products targeted were of two broad classes: 1) synthetic marijuana “incense” products comprised of naphthoylindole cannabimimetic compounds first synthesized by John W. Huffman’s lab at Clemson in the mid-1990s, and 2) “bath salts” or “plant food” products containing the stimulant/empathogen mephedrone (4-methylmethcathinone) or the stimulant MDPV (3,4-methylenedioxypyrovalerone).
This compilation of posts on synthetic marijuana and, to a lesser extent, “bath salts” serves as a good primer on the subject.
Sixteen-year-old boys having heart attacks.
Blog reports of deaths and suicides.
And a little known chemistry and public health resource mobilized to identify “legal highs.”
The chemical and biological phenomenon that is “synthetic marijuana” continued to develop over the last week as we learn more about these products from the medical and public health communities.
Most notably, pediatric cardiologists reported in the journal Pediatrics on three cases of Texas teenagers who experienced myocardial infarctions – heart attacks – after using a synthetic marijuana product (DOI: 10.1542/peds.2010-3823).
For those following our most persistent story of the last year or so, you’ve already heard that the US Drug Enforcement Administration declared as controlled substances five synthetic cannabimimetics present in “herbal incense” products such as K2 Spice, Mr. Nice Guy, and Blaze. These compounds include JWH-018, JWH-073, JWH-200, CP-47,497, and cannabicyclohexanol.
With respect to our chemistry audience here, I discussed on New Year’s Eve how the DEA has authority to also regulate “analogues” [sic] of compounds that have been assigned to Schedule I of the Controlled Substances Act. This amendment to the act gives the DEA latitude to prosecute the sale, use, and possession of chemical analogs or compounds pharmacologically-similar to those explicitly listed as controlled substances. What authority decides what’s an analog or not is still a mystery to me and was the subject of that post.
Earlier this week, I wrote about on the comprehensive chemistry text in two North Carolina state bills – H12/S9 and H13/S7 – to criminalize distribution, sales, and possession of compounds present in a variety of legal-high, designer drug products.
One bill specifically addressed compounds present in synthetic marijuana compounds whose extensive list included those eponymous JWH compounds synthesized in the laboratory of Clemson University Professor Emeritus, John W. Huffman (featured here). The other bill addressed mephedrone (4-methylmethcathinone; 4-MMC) and other structural analogs of this amphetamine and cathinone derivative.
However, I noted my surprise at the time at the omission of a compound more commonly associated with so-called bath salt products: MDPV, or methylenedioxypyrovalerone. My neuroscience blogging colleague DrugMonkey also remarked to me of his surprise since most other states deal with MDPV in the same legislation with mephedrone/4-MMC because of their structural similarity.